Syntiron
Syntiron is a human vaccine research firm dedicated to developing innovative vaccines to combat antimicrobial resistant bacteria. Their mission is to create broad, effective, and easy-to-manufacture vaccines, leveraging their proprietary Alloy Vaccine Platform that targets bacterial metal receptors. They focus on addressing global health challenges such as antimicrobial resistance, urinary tract infections, neonatal sepsis, and other bacterial infections, with a strong emphasis on vaccine development and partnerships to advance human health.
Industries
Nr. of Employees
small (1-50)
Syntiron
Saint Paul, Minnesota, United States, North America
Products
Synthetic protein vaccine platform targeting bacterial metal transport proteins
A vaccine platform that engineers antigens from conserved peptide sequences derived from bacterial metal/iron receptor proteins to generate stable, broadly protective recombinant protein vaccines.
Synthetic protein vaccine platform targeting bacterial metal transport proteins
A vaccine platform that engineers antigens from conserved peptide sequences derived from bacterial metal/iron receptor proteins to generate stable, broadly protective recombinant protein vaccines.
Services
Collaborative vaccine R&D and preclinical development
Contract or partnership-based vaccine discovery and preclinical services including antigen design, immune profiling, and animal model testing to advance candidates toward clinical readiness.
Partnerships, licensing and funded project execution
Licensing of vaccine technology for human applications, management of intellectual property, and execution of grant- or contract-funded development projects.
Collaborative vaccine R&D and preclinical development
Contract or partnership-based vaccine discovery and preclinical services including antigen design, immune profiling, and animal model testing to advance candidates toward clinical readiness.
Partnerships, licensing and funded project execution
Licensing of vaccine technology for human applications, management of intellectual property, and execution of grant- or contract-funded development projects.
Expertise Areas
- Bacterial vaccine discovery
- Antigen engineering and design
- Recombinant protein vaccine manufacturing
- Preclinical vaccine development
Key Technologies
- Recombinant protein expression
- Bioinformatics-driven antigen design
- Protein engineering of conserved peptide constructs
- In vivo and in vitro infection models